None listed
Conditions
Interventions
Drug : Case : Mirabegron 50mg once a day for 2 weeks
Control : No additional treatment for 2weeks
Sponsors
Korea University Ansan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients to be undergone double J stent indwelling after flexible or rigid ureteroscopic stone removal. 1. =20 years 2. Undergoing unilateral retrograde double-J (DJ) stent (6Fr) placement planned for 5-28 days indwelling (only after ureteroscopic procedure, retrograde intrarenal surgery)
Exclusion criteria
Exclusion criteria: 1. After percutaneous nephrolithotomy, open or laparoscopic ureterolithotomy 2. Presence of ureteral stone 3. Renal insufficiency (serum Cr > 1.7) 4. Febrile UTI (fever > 38°, evidence of urinary infection) 5. Pregnancy or breast feeding 6. Solitary kidney 7. Hypersensitivity to mirabegron 8. Current use of any alpha-blocker, calcium-channel blocker, corticosteroid, Anti-muscarinic agents (within 4 weeks) 9. Moderate or severe cardiovascular or cerebrovascular disease 10. Hepatic dysfunction (>2 x normal LFT) 11. Prior history of pelvic surgery or irradiation 12. Prior history of TURBT or prostate surgery 13. Significant active medical illness which in the opinion of the investigator would preclude protocol treatment 14. Genetic disorder such as Galatose intolerance, Lapp Lactase deficiency, Glucose-Galactose malabsorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| USSQ urinary symptom score (Body pain score) | — |
Secondary
| Measure | Time frame |
|---|---|
| USSQ general health score;USSQ work performance score;IPSS (International prostate symptom score)/ QoL score;additional analgesics use;Post voiding residual urine volume | — |
Countries
Korea, Republic of
Contacts
Public ContactBum Sik Tae
Korea University Ansan Hospital
Outcome results
None listed